Article

Dynamic stimulation aberrometer objectively measures presbyopic accommodation during wavefront exam

San Francisco-The dynamic stimulation aberrometer provides "objective and observer-independent measurements of accommodation and is a suitable instrument for the planning of treatment of presbyopia," said Matthias Elling, MD, Ruhr University Eye Hospital, Bochum, Germany.

San Francisco-The dynamic stimulation aberrometer provides “objective and observer-independent measurements of accommodation and is a suitable instrument for the planning of treatment of presbyopia,” said Matthias Elling, MD, Ruhr University Eye Hospital, Bochum, Germany.

According to Dr. Elling, the dynamic stimulation aberrometer allows for binocular accommodation stimulation while regular wavefront measurements are being taken.

Dr. Elling and his colleagues analyzed accommodation in 598 eyes in 299 patients with presbyopia. The age range of the patients was 10 to 60 years, and the average age was 37 years. One investigator conducted three measurements of each eye in patients with emmetropia, myopia, and hyperopia.

The subjects were asked to focus on a distance target for 3 seconds, then a near target for 3 seconds, then a distance target again for 3 seconds. During the 9-second test, a total of 300 measurements were performed using the dynamic stimulation aberrometer, Dr. Elling said. The researchers analyzed the range of accommodation based on age and ametropia.

“The measurements were highly accurate,” Dr. Elling said. “Based on our study, we feel this is an effective technology to objectively visualize and analyze the change in accommodation range within presbyopia, with consideration of patient age and ametropia.”

The dynamic stimulation aberrometer also allows for visualization of wavefront aberrations, Dr. Elling concluded.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
© 2024 MJH Life Sciences

All rights reserved.